Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Innovation Pharmaceuticals IPIX
(Total Views: 1240)
Posted On: 05/20/2017 1:58:28 PM
Post# of 72447
Avatar
Posted By: someconcerns
Re: Drano #33990
Georgejjl post over there:

Quote:
georgejjl Saturday, 05/20/17 09:16:54 AM
Re: None
Post # of 182687


Quote fizer acquired Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes



In 2010:

Quote:Anacor Pharma Prices IPO at $5 a Share



http://www.pfizer.com/news/press-release/pres...ire_anacor

Dare to compare Cellceutix to Anacor.

Strong fit with Pfizer’s Inflammation and Immunology portfolio

Expected to enhance near-term revenue growth for the innovative business
Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis

Brilacidin
Inhibits PDE4 and Suppresses Cytokines/Chemokines, Lessening Inflammation and Promoting Healing

Brilacidin’s inhibition of PDE4—a predominant phosphodiesterase expressed in neutrophils, T cells, macrophages and keratinocytes—
leads to an increase in the intracellular cAMP concentration, thereby reducing the production of pro-inflammatory mediators and
increasing anti-inflammatory mediators.

Additional research is underway to determine Brilacidin’s role in regulating IL-17, a central driver most inflammatory diseases,
including many skin diseases.

Phosphodiesterase inhibition assays demonstrated that Brilacidin inhibits both PDE4B2 (IC50 of 2.5 ± 0.21µM;
n=5) and PDE3A (IC50 of 1.5 ± 0.2µM; n=4) in a dose dependent manner.
The PDE-Glo phosphodiesterase assay was performed using 8ng of PDE4B2 and 2.75ng of PDE3A, respectively,
with 1µM cAMP substrate and indicated amount of Brilacidin.
Brilacidin and PDE4B2 and PDE3A, respectively, were mixed and pre-incubated at room temperature for
15minutes. Substrate was added and the reaction was incubated for 7 minutes at room temperature.

https://static1.squarespace.com/static/571535...e+Vers.pdf

Good luck and GOD bless,

George














(1)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site